<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02020954</url>
  </required_header>
  <id_info>
    <org_study_id>Becker-Heart-Study</org_study_id>
    <nct_id>NCT02020954</nct_id>
  </id_info>
  <brief_title>Prospective Becker-Heart-Study</brief_title>
  <acronym>Becker-HS</acronym>
  <official_title>Prospective Cohort Study of Patients With Mutations in the Dystrophin Gene (X Linked Dilated Cardiomyopathy and Becker Muscular Dystrophy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karim WAHBI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Myologie, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Myologie, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether electrocardiogram, echocardiography,&#xD;
      cardiac MRI, sera biomarkers can improve early detection of myocardial involvement and&#xD;
      clinical outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A cohort of 100 patients with mutations in the dystrophin gene associated with Becker&#xD;
      muscular dystrophy and/or dilated cardiomyopathy will be included (patients with Duchenne&#xD;
      muscular dystrophy are excluded).&#xD;
&#xD;
      Patients with undergo at baseline the following workups: electrocardiogram, echocardiography,&#xD;
      cardiac MRI, sera biomarkers measurement.&#xD;
&#xD;
      At 3 years and 5 years, patients will be investigated according to the same protocol and&#xD;
      occurrence of cardiac adverse events in the meanwhile will be recorded.&#xD;
&#xD;
      Statistical analysis will assess correlations between cardiac phenotype and DMD mutations and&#xD;
      prognostic value of cardiac investigations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint: hospitalisation for heart failure, death due to heart failure</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <condition>Lef Ventricular Dysfunction</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Dystrophinopathy</arm_group_label>
    <description>Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated cardiomyopathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ECG, echocardiography, cardiac MRI, sera biomarkers</intervention_name>
    <arm_group_label>Dystrophinopathy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated&#xD;
        cardiomyopathy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  mutation in the DMD gene&#xD;
&#xD;
          -  Becker muscular dystrophy and/or dilated cardiomyopathy&#xD;
&#xD;
          -  age&gt;18 years&#xD;
&#xD;
          -  affiliation to the French medical insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Duchenne muscular dystrophy&#xD;
&#xD;
          -  Any other chronic disease that may be associated with heart disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Wahbi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Myologie, Cochin Hospital, Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karim Wahbi, MD, PhD</last_name>
    <email>karim.wahbi@cch.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Myologie</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nawal Berber, PhD</last_name>
      <email>n.benammar@institut-myologie.org</email>
    </contact>
    <investigator>
      <last_name>Karim Wahbi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>December 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2013</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Myologie, France</investigator_affiliation>
    <investigator_full_name>Karim WAHBI</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

